Background
What it is, how it developed and why it is discussed
CJC-1295 is a growth-hormone-releasing-hormone analogue, while ipamorelin acts at the ghrelin receptor. Both have been investigated for effects on growth-hormone secretion.
A growth-hormone secretagogue pathway requiring specialist medical review.
A consultation does not guarantee that a product can be supplied.
This treatment is not enabled for routine online sale. A doctor can discuss the evidence, suitability and lawful alternatives. Where an unregistered medicine is considered clinically necessary, any access must follow the applicable SAHPRA authorisation process before supply.
Clinical assessment Clinician authorisation